Use of alendronate and risk of incident atrial fibrillation in women

Archives of Internal Medicine

Volumn 168, Issue 8, 2008, Pages 826-831

  Heckbert, Susan R ^a,b,c   Li, Guo ^a,b   Cummings, Steven R ^d   Smith, Nicholas L ^a,b,e   Psaty, Bruce M ^a,b,c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c CENTER FOR HEALTH STUDIES   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; ZOLEDRONIC ACID;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DRUG USE; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; STATISTICAL ANALYSIS; UNITED STATES;

AGED; AGED, 80 AND OVER; ALENDRONATE; ATRIAL FIBRILLATION; BONE DENSITY CONSERVATION AGENTS; CASE-CONTROL STUDIES; DIABETES MELLITUS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; OSTEOPOROSIS, POSTMENOPAUSAL; RISK ASSESSMENT;

EID: 42949145038     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.168.8.826     Document Type: Article

References (23)